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Abstract 
 
 
 
 
Allogeneic stem cell (SC)-based therapy is a promising tool for the treatment of a 
range of human degenerative and inflammatory diseases. Many reports highlighted the 
immune modulatory properties of some SC types, such as mesenchymal stromal cells 
(MSCs), but a comparative study with SCs of different origin, to assess whether 
immune regulation is a general SC property, is still lacking. To this aim, we applied 
highly standardized methods employed for MSC characterization to compare the 
immunological properties of bone marrow (BM)-MSCs, olfactory ectomesenchymal 
SCs (OE-MSCs), leptomeningeal SCs (LeSCs), and three different c-Kit-positive SC 
types, that is, amniotic fluid SCs (AFSCs), cardiac SCs (CSCs), and lung SCs (LSCs). 
We found that all the analyzed human SCs share a common pattern of immunological 
features, in terms of expression of activation markers ICAM-1, VCAM-1, HLA-ABC, 
and HLA-DR, modulatory activity toward purified T, B, and NK cells, lower 
immunogenicity of inflammatory-primed SCs as compared to resting SCs, and 
indoleamine-2,3-dioxygenase (IDO)-activation as molecular inhibitory pathways, with 
some SC type-related peculiarities. Moreover, the SC types analyzed exert an anti-
apoptotic effect toward not-activated immune effector cells (IECs). In addition, we 
found that the inhibitory behavior is not a constitutive property of SCs, but is acquired 
as a consequence of IEC activation, as previously described for MSCs. Thus, immune 
regulation is a general property of SCs and the characterization of this phenomenon 
may be useful for a proper therapeutic use of SCs. 
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Chapter 1   
 
 
 
 
Introduction 
 
 
1.1 Stem cells and their microenvironment 
 
 
The possibility to use mammalian stem cells (SCs) as novel, accessible and versatile 
tools for clinical applications has raised much interest in the recent years. This 
possibility is related to their “plasticity”, which makes SCs effectors of therapeutic 
tissue regeneration. The “stemness" of SCs reside in their undifferentiated state, that is 
the ability at single cell level to self-renew and generate multiple differentiated cell 
types[1]. The differentiation potential is the main feature of SCs, which depends on 
their origin and by their capacity to generate specific cellular lineages. SCs can be 
classified on the basis of their potential capabilities. The categories into which SCs fall 
include: (1) totipotent SCs that produce all embryonic and extra-embryonic cell 
lineages; (2) pluripotent SCs, also known as embryonic stem cells (ESC), isolated for 
the first time from the inner cell mass of blastocyst and having the capabilities to 
generate all cells of the embryo proper[2,3]; (3) multipotent SCs that have the ability to 
differentiate only a subset of cell lineages; (4) oligopotent SCs, which have a minor 
differentiation potential than multipotent SCs and finally (5) unipotent SCs that may 
generate only one cell type.  
Intrinsic tissue regeneration is a feature shown by the majority of metazoan, and this 
mechanism has been attributed to resident SCs, which maintain the balance between 
proliferation and the generation of differentiated offspring. This balance is obtained 
thanks to the ability of SCs to divide into a new SC and a progenitor. Thus, the tissue 
homeostasis is maintained by the self-renewal of SCs, which can be regulated through 
an extrinsic or an intrinsic mechanism. The intrinsic mechanism occurs during cell 
mitosis, in which the regulators of self-renewal are distributed asymmetrically into the 
two daughter cells. This phenomenon happens because during interphase SCs can set 
up an axis of polarity, distributing differently the protein determinants in the 
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cytoplasm[4,5]. The extrinsic mechanism depends on microenvironment in which the 
specific SC resides, which is known as “SC niche”. In this mechanism, the SC that are 
in close contact with SC niche, orients its mitotic spindle perpendicularly to the niche 
surface and, at the end of cell division, the daughter cell that maintains the contact with 
niche, retain the ability of self-renewal [5,6] (Figure 1). Occasionally the division axis 
can be orientated parallel to the niche, determining an increase the number of SCs and 
in some cases balancing the loss SC pool. Normally, the extrinsic mechanism is more 
common in adult SCs respect to the intrinsic mechanism, which occurs during 
development[5]. 
SC niche is a complex structure in which different cell types, soluble factors and 
physical cues, such as oxygen tension or temperature, orchestrate the balance between 
quiescence, proliferation and commitment of SCs. The influence that the 
microenvironmental has on SC homeostasis must not be underestimated, because all 
components within the niche are responsible of the physiological funtion of SCs.  
 
 
 
Figure 1. Extrinsic and Intrinsic Mechanism of Stem Cell Self- Renewal. In the upper panel is shown the 
intrinsic mechanism in which SCs can set up an axis of polarity during interphase and use it to localize cell fate 
determinants asymmetrically in mitosis. Orientation of the mitotic spindle along the same polarity axis ensures the 
asymmetric segregation of determinants into only one of the two daughter cells. In the lower panel is shown the 
extrinsic mechanism in which SCs are influenced surrounding niche for self-renewal. By orienting their mitotic 
spindle perpendicularly to the niche surface, they ensure that only one of the two daughter cells continues to receive 
this signal and maintains the ability to self-renew. (modified from[5]). 
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An example of SC niche is the bone marrow (BM), which constitutes the 
microenvironmental that regulates the hematopoietic stem cell (HSC) homeostasis[7]. 
In 1978 Schofield proposed for the first time the concept of BM niche, in which HSCs 
were closely associated with BM microenvironment. Today, HSCs are the best-
characterized multipotent SCs. These SCs have been isolated for the first time from 
mouse BM about 15 years ago[8]. Today, it is widely known that multipotency, self-
renewal capacity and the quiescence of HSCs are regulated by different factors inside 
BM. These signals can be generated by different BM cell populations, but also by 
physical factors. The latter are mainly related to the concentration of oxygen. In fact, 
when HSCs are into the endosteal region, where the low levels of oxygen[9-11], 
maintain their self-renewal capabilities[12]. It has been demonstrated that the 
disruption of hypoxia-inducible factor (HIF)-1α resulted in loss of HSC quiescence, 
while the presence of this molecules induced quiescence and increased repopulating 
activity[13,14]. 
On the other hand, inside BM niche there are various populations of stromal cells, 
which support the hematopoiesis (Figure 2). These SC populations include: 
osteolineage cells, implicated in HSC regulation through the release several cytokines, 
such as granulocyte colony-stimulating factor (GM- CSF)[15], thrombopoietin[16], 
and CXCL12[17]; perivascular CXCL12-expressing stromal cells, which include 
CXCL12-abundant reticular (CAR) cells, nestin positive stromal cells and leptin 
receptor positive stromal cells, and MSCs[18-20] (Figure 2). 
Thus, the study of SCs must not only be focus on cell population of interest but, 
defining niche components and how they work in concert to regulate SC homeostasis 
could provide the opportunity to improve regeneration following injury and understand 
how disordered niche function could contribute to disease.  
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1.2 Mesenchymal Stromal Cells (MSCs) 
 
 
MSCs are a population of multipotent SCs identified for the first time between the 
1960s and 1970s. At that time, Friedenstein and his colleagues studied a subpopulation 
of BM cells with osteogenic capabilities, which were confirmed through heterotopic 
transplantation[21]. In fact, when this BM cells were transplanted into subcutaneous 
space or in kidney, they were able to form ectopic marrow, including trabecular bone, 
adipocytes and myelosupportive stroma.  
Successively, the same group demonstrated that these BM cells were able to adhere to 
tissue culture plastic, generate colony forming unit (CFU), showing a fibroblast-like 
morphology[22]. 
 
 
 
 
 
Figure 2. Haematopoietic stem cells (HSCs) niche. HSCs are localized near to sinusoids in the BM, where 
endothelial cells and MSCs regulate HSC homeostasis by release of stem cell factor (SCF), CXCL12 and other 
factors. Also other cells are involved in the HSC maintenance such as perivascular stromal cells, including CAR 
cells, but also sympathetic nerves, non-myelinating Schwann cells, macrophages and osteoclasts. (modified 
from[7]).
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A few years later, other research groups have been determined that BM stromal cells 
can be expanded in vitro for long term culture, and supported the haematopoiesis[23]. 
In the same period, Caplan described these BM cells as mesenchymal “stem” cells, for 
their ability to generate different cells of mesodermal lineage[24]. However, the MSC 
differentiation potential toward adipose tissue, bone and cartilage was later shown[25]. 
Today, several research groups are focusing the attention on the study the 
mesenchymal stromal/stem cells (MSCs) not exclusively for their differential 
capabilities, but also for their ability to support haematopoiesis and regulate the 
immune response.  
MSCs can be also isolated from other tissues, including adipose tissue[26], 
placenta[27], amniotic fluid[28], Wharton’s jelly[29] and dental pulp[30]. The growing 
interest in the use of MSCs for clinical applications has led to an increase of 
publications in the last decade. Currently, PubMED identify about 33.000 references 
for mesenchymal stem cells and over 20.000 for mesenchymal stromal cells. The 
continuous amount of publications led to growing insights on MSCs, but also to an 
increase of heterogeneous data. In fact, there are different terminologies to identified 
MSCs, but also different methods of isolation and approaches to expand and 
characterize the cells.  
To overcome these issues, the committee of International Society for Cellular Therapy 
(ISCT) has proposed the minimal criteria to define human MSCs[31,32]. First of all, 
the Authors defined the fibroblast-like plastic-adherent cells as “Mesenchymal Stromal 
Cells” regardless of the tissue from which they are isolated to overcome the 
inconsistency between nomenclatures and facilitate exchange of knowledge among 
biomedical investigators[31]. However, given that not all these cells are SCs, the term 
mesenchymal stem cells was specifically used to identify the subpopulation of cells 
that showed stem cell features, i.e. a long-term self-renewal and the capability to 
differentiate into different specific lineage in vivo. For example, the cells isolated from 
BM through plastic adherence are not uniform cell population, and this aspect is 
proven by the relative small fraction of these cells to produce fibroblast colonies 
(CFU-F), even if all these cells showed multipotentialy. Thus, since it is difficult to 
discriminate the different subpopulation, the Authors suggested the term mesechymal 
stromal cells to avoid misunderstanding.  
Thereafter, ISCT Committee proposed the minimal criteria to define MSCs[32]. They 
suggested three criteria that are: (1) the adherence to plastic, (2) the specific surface 
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antigen expression, and (3) the multipotent differentiation potential (Table 1). 
Specifically, to identify a MSC, at least the 95% of population must express CD105 
(endoglin, SH2), CD90 (Thy1) and CD73 (ecto-5’-nucleotidase) defined mesenchymal 
markers, as measured by flow cytometry. Furthermore, the MSC population must lack 
expression (≤2% positive) of CD45, CD34, CD14 or CD11b, CD79α or CD19 and 
HLA class II. The multipotent differentiation potential was instead defined by their 
ability to differentiate toward osteoblasts, adipocytes and chondroblasts under specific 
stimuli in vitro. 
Many studies have reported that MSCs can also trans-differentiate into multiple cell 
types of mesodermal and non-mesodermal origin, such as endothelial cells[33], 
cardiomyocytes[34], hepatocytes[35] and neural cells[36], although this MSC feature 
in not universally accepted. 
Despite, the identification of MSCs by use of specific markers is an simple procedure, 
the same is not so easy in vivo[37]. However, the use of some markers, such as nestin, 
leptin receptor, Gli1, and FAP has followed the identification of tissue resident MSCs, 
and the study of migration and function of injected MSCs, after population expansion 
in vitro[38-40]. Mendez-Ferrer and colleagues have been identified a population 
nestin-expressing cells into endosteal niche[41]. These cells showed MSC features, as 
defined by their ability to form colony-forming unit fibroblast. They have been shown 
for the first time that MSCs are the progenitors of mature osteochondral cells in BM, 
and that these cells are essential for the maintenance of the niche by supporting 
haematopoiesis SCs function[41]. 
Although the identification of physiologic function of resident MSCs needs to be 
clarified, the effects of in vitro expanded MSCs has provided important clues about 
their roles in vivo, especially in disease models. When MSCs are injected in vivo, they 
are able to migrate toward the damage tissues, such as infarcted myocardium, 
traumatic brain injury or fibrotic liver where they play an important role in tissue 
repair[42]. MSCs are able to migrate toward damage tissue, where they exert beneficial 
effects both by the replacement of damage cells that by release of soluble factors. 
Particularly, in presence of inflammatory stimuli, such as TNF-α, lipopolusaccharide 
or hypoxia, MSCs release various growth factors, including epidermal growth factor 
(EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), 
transforming growth factor (TGF-b), vascular endothelial growth factor (VEGF), 
hepatocyte growth factor (HGF), insulin-like growth factor (IGF)-1, angiopoietin-1 
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and stromal cell-derived factor (SDF)-1, which promote the tissue repair[43,44]. 
Moreover, these molecules can activate resident cells, such as endothelial cells and 
fibroblast, which are important for the angiogenesis and remodelling of the 
extracellular matrix respectively, and resident progenitor cells that can be induced to 
differentiate in specialized tissue cells (Figure 3).  
 
 
 
  
1. Plastic adherence 
 
2. Phenotype 
 
Positive (≥95% +) 
 
Negative (≤2% +) 
 CD105 CD45 
 CD90 CD34 
 CD73 CD14 or CD11b 
  CD79α or CD19 
  HLA class II 
 
3. In vitro capability to differentiate to osteoblasts, adipocytes and chondroblasts. 
 
Table 1. Minimal criteria to define Mesenchymal Stromal Cells (MSCs). 
 
 
 
 
1.2.1 MSCs, Inflammation and Immunomodulation 
 
Several Authors have been shown the efficacy of MSCs in preclinical and clinical 
studies, but this capability has not always been confirmed. In fact, most of injected 
MSCs previously expanded in vitro remain trapped in the lungs. On the other hand, the 
MSCs that reach the damaged tissues have a poor rate of engraftment, and remain 
active for short period. This aspect suggests that the effects of MSCs are not limited to 
replacement of these cells into the site of injury, but probably molecule released by 
MSCs can play a crucial role in this scenario[45,46]. For example, it has demonstrated 
that the use of supernatants of MSCs, including molecules such as TSG6 and HGF, can 
improve inflammatory diseases, improving cardiac function during myocardial 
infarction and promote the recovery in EAE, respectively[47,48].  
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Figure 3. Effect of MSCs in tissue regeneration and immune regulation. MSCs are able to reach the tissue 
damaged when injected in vivo, where they can differentiate into functional cells to replace damaged cells. 
Alternatively, MSCs by realising of growth factors can stimulate resident cells, including endothelial cells, 
fibroblasts and, most importantly, tissue progenitor cells, which help the tissue repair through angiogenesis, 
remodeling of the extracellular matrix (ECM) and the differentiation of tissue progenitor cells. Moreover, the 
inflammatory microenvironmental induce MSC switch toward an immunosuppressive status and in turn to modulate 
the inflammatory response. (Modified from[49])  
 
 
 
The therapeutic effects of MSCs are not only associated to their ability to regulate the 
tissue remodelling by secretion of different cytokines and growth factors, but also to 
their ability to regulate the immune response (Figure 3). The immunomodulation is a 
peculiar feature of MSCs, with which these cells influence both adoptive and innate 
immunity.  
MSCs carry out a double function, by switching from an anti-inflammatory to 
proinflammatory status, interacting with different components of immune 
system[50,51]. The immunomodulatory effects of MSCs have been displayed for 
different IECs of acquired immunity, such as T- and B-cells, but also for cells of innate 
immunity, including NK-cells, monocytes, macrophages and neutrophilis. Several 
reports have been shown the ability of MSCs to modulate the immune system both in 
vitro that in vivo, sometimes with conflicting data. However, they have provided the 
basis for the MSC clinical application for disorders resulting from autogenic or 
allogeneic immune response, such as Graft-versus-Host Disease (GvHD), multiple 
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sclerosis, and other autoimmune disorders[50,52].  
Actually, MSCs are not constitutively immunosuppressive cells. During physiological 
conditions they show anti-apoptotic and supportive properties toward different cell 
types, such as HSCs, IECs, plasma and neoplastic cells[50]. The immune modulatory 
properties of MSCs are associated to the inflammatory microenvironment. In presence 
of specific cytokines, mainly interferon (IFN)-γ, tumor necrosis factor-α (TNF-α) and 
interleukin (IL)-1α/β, MSCs can switch toward a proinflammatory or anti-
inflammatory status, for this reason this SCs have been described as “sensor of 
inflammation”[51]. This double function is related to the levels of these inflammatory 
cytokines. For instance, during the early phase of inflammation, when the levels of 
cytokines are low, MSCs adopt a proinflammatory phenotype, supporting the 
development of inflammatory response. Conversely, during the late phase of 
inflammation, the levels of cytokines are higher due to the constant release of 
cytokines by IECs in the microenvironment, and the MSCs differentiate toward the 
anti-inflammatory phenotype.  
Thus, the MSCs are regulators of immunity response and modulate the balance 
between the activation and suppression of inflammation. However, to better understand 
how MSCs suppress the IECs is important to focus the attention on the impact of the 
inflammatory microenvironment on MSCs. 
Inflammation is a protective response trigger by infection or tissue injury, which helps 
to eradicate pathogens and restored host integrity. During the onset of inflammation, 
the first cells implicated in the inflammatory response are the innate effector cells, 
mainly phagocytes, such as macrophages and neutrophils[53]. These cells express on 
their plasmatic membrane specific receptors, such as the molecules belonging to the 
family of Toll-like receptors (TLRs), which are activated by molecules associated with 
pathogens or cell stress. These ligands are known also as pathogen-associeted 
molecular patterns (PAMPs), and they are evolutionarily conserved in the different 
species. PAMPs include the endotoxin bacterial lipopolysaccharide (LPS), recognized 
by TLR4, the flagellin, recognized by TLR5, and the PAMPs normally associated with 
virus, that is double-stranded RNA (dsRNA), which act on TLR3[54].  
TLRs are not exclusively express by phagocytes but also by MSCs[54,55]. It has been 
demonstrated that the expression of TLRs on MSCs contributes to their polarization. 
For instance, the activation of TLR4 on MSCs, induces the change toward the 
proinflammatory phenotype, while the activation of TLR3 polarize the MSCs toward 
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the anti-inflammatory status[56]. Thus, the MSC polarization should be seen how a 
synergic collaboration between the inflammatory cytokines and the TLR-activation. In 
fact, during the onset of inflammation, the secretion of inflammatory cytokines, induce 
an overexpression of TLRs on MSCs, which become more responsive to inflammatory 
microenvironment. On the contrary the high concentration of cytokines and the 
protracted stimulation of MSCs, induce a downregulation of TLR2 and TLR4, which 
are mainly involved in proinflammatory response, and consequently cause a 
suppressive polarization of MSCs mainly driven by TLR3[56]. 
Similarly to MSCs, monocytes can differentiate into macrophages with a 
proinflammatory (M1) or an anti-inflammatory (M2) function, and this polarization 
can be influenced by MSCs. In fact, the production of IL-6 by MSCs induce a 
polarization of monocytes toward the anti-inflammatory status, on the contrary the lack 
IL-6 release allows the switch toward the proinflammatory phenotype[51]. 
The anti-inflammatory M2 cells are able to secrete cytokines including IL-10, TGF- β 
and low levels of IL-1, IL-6, IFN-γ and TNF-α[51].  
In addition to monocytes, MSCs interact with other components of innate immunity. 
For instance, the secretion of IL-6, Il-8, GM-CSF and macrophage migration inhibitory 
factor by MSCs induce the recruitment of neutrophils, which collaborate with other 
cells into the site of inflammation to increase the immune response[57,58]. In this 
scenario, the relationship of MSCs with effector cells of innate immunity is essential to 
maintain the correct balance between activation and inhibition of inflammatory 
response. 
The recruiting activity of MSCs involved also other IECs. In particular, after 
inflammatory cytokine stimulation, MSCs secrete molecules belonging to the family of 
(C-X-C motif) ligand, such as CXCL-9, CXCL-10 and CXCL-11, and to (C-C motif) 
ligand, such as CCL2, CCL3 and CCL12, which are involved in the recruitment of 
different components of innate immunity, as monocytes, macrophages but also of 
different type of lymphocytes[52].  
All these mechanisms generate a loop of signals that lead to a correct development of 
an inflammatory response, which induce the immunosuppressive phenotype of MSCs. 
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1.2.2 MSC-mediated Immunosuppression  
 
The progression of inflammation together with the recruiting of different IECs into the 
inflammatory site, result in an amount of inflammatory cytokines, which are 
responsible of MSC differentiation toward the immunosuppressive status. This 
process, known as priming or lincesing of MSCs, is mainly induced by the presence of 
IFN-γ and by the activation of its receptor IFN-γR1[50]. It has been demonstrated that 
the blockage of IFN-γ or its receptor IFN-γR1 by use of specific antibodies, reverted 
the MSC-mediated immunosuppression[59]. Also the other inflammatory cytokines, 
including TNF-α and IL1α/β, taking active part in this mechanism but are primarily 
involved in the enhancing of MSC licensing[50]. 
The next question that needs to be discussed is how primed MSCs inhibit the immune 
response.  
Different reports have been shown a large number of MSC immunosuppressive 
molecules, including interferon-γ (IFN-γ)[59,60], interleukin-1β (IL-1β)[61],  
transforming growth factor-β[62-64], indoleamine-2,3-dioxygenase (IDO)[59,65], IL-
6[66,67], IL-10[68], prostaglandin-E2 (PGE2)[44], hepatocyte growth factor[62], 
TNF-α[69-71], nitric oxide (NO)[72], heme oxygenase-1 (HO-1)[73], HLA-G5[74,75], 
and many other factors, some of which are still unidentified. 
The MSC immunosuppression is a conserved and species-specific mechanism[76]. It 
has been shown that BM-MSCs derived from human, monkey and pig use mainly IDO 
to inhibit IEC proliferation, whereas BM-MSCs from mouse, rat, hamster and rabbit 
generally utilized iNOS expression.  
This change in the immunosuppression mechanism is not related to the lack of 
expression of these molecules in the different species, but for a singular mechanism of 
regulation. In fact, even if human IDO shares 62% sequence homology with the mouse 
IDO, only in human there is an upregulation of this molecule following IFN-γ 
induction[77-79]. 
IDO is an enzyme involved in the catabolism of the tryptophan (TRP). It acts in two 
different ways. The first is the production of kynurenine (KYN), which binds the aryl 
hydrocarbon receptor (AhR) on target cells, consequently causing suppression, anergy 
or cellular death. In addition, the AhR pathway can promote differentiation of 
forkhead-box (Fox)p3+ T regulatory (Tregs) cells, which lead to an increased of 
immunosuppression[80,81]. 
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The second mechanism is related to the depletion of TRP by IDO, which in turn, acts 
on the cell vitality. Moreover, the TRP reduction trigger the molecular stress-response 
pathways on target cells, such as GCN2 kinase and the mammalian target of rapamycin 
(mTOR)[82] (Figure 4).  
The role of IDO in MSC-mediated immunosuppression has been confirmed by use of 
L-1MT, the specific inhibitor of IDO. Similarly, the addition of tryptophan into 
MSC/T cell coculture restored T cell proliferation[65]. 
In addition to MSCs, different types of antigen-presenting (APC) cells, including 
dendritic cells (DCs) and macrophages utilized IDO mechanism to suppress the 
proliferation of T and NK cells[82]. 
Differently from human, mouse MSCs suppress the IEC proliferation by the expression 
of iNOS, which is also modulated by the presence of IFN-γ, TNF-α and IL-1-α/β. NO 
released by MSCs induce the activation of STAT5 pathway in T cells, which lead to 
the apoptosis of these IECs in vitro[72]. The effect of iNOS has been confirmed by use 
of specific inhibitors, which reverted the MSC-mediated immunosuppression both in 
mouse model of GvHD that after heart allograft transplantation in rat model[73,83]. 
Unlike IDO, NO have a short-range effect due to its low stability when released into 
microenvironment, thus its effect decreased as the distance from the cells secreting 
it[84]. However, following inflammatory priming the secretion of chemokines and the 
overexpression adhesion molecules by MSCs, including ICAM-1 (CD54) and VCAM-
1 (CD106), lead to the recruitment and tethering of IECs in close proximity to the 
MSCs, where the NO concentration is higher to be efficacy[83,85]. 
IDO and NO are not the only molecules involved in MSC-mediated 
immunosuppression. It has been demonstrated that the inhibition of cyclooxygenase-2 
(COX-2), the enzyme that produces PGE2, restored proliferation of T cells when 
cultured with MSCs[44,86]. 
The effects of MSC suppressive molecules have been shown for different IEC 
population. For example, MSCs can inhibit different subsets of proinflammatory T 
cells, including TH1 and TH17, but also MSCs can polarize the T cells toward a 
regulatory phenotype, thus improving the anti-inflammatory mechanism[87].  
Similarly to the effect previously shown for KYN pathway, the production of PGE2, 
TGF-β or HLA-G5 by human MSCs induced a differentiation of CD4+ T cells toward 
CD25+FoXP3+ Tregs when MSCs were cultured in presence of PBMCs[74,88,89].  
MSC-mediated immunosuppression is not only a direct mechanism mediated by 
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release of molecules directly, but MSCs can induce other cells to suppress the IECs. 
For example, MSCs can induce the differentiation of Tregs also by activation of TGF-β-
produced macrophages or by induction of DCs via IL-10[90,91]. 
 
 
 
 
 
 
Figure 4. Mechanism of IDO. Metabolic control of T cells and Tregs responses via IDO. The release of KYN and 
TRP consumption by accessory cells expressing IDO generates signals via AhR and amino-acid sensors (GCN2, 
mTOR), respectively, that have profound effects on T cell and Tregs responses to inflammatory and antigenic signals. 
IDO activity in MSCs also enhances Tregs differentiation from naive CD4 T cells via these metabolic pathways. 
(modified from[82]). 
 
 
 
On the other hand, the release of PGE2 by MSCs inhibits the differentiation, 
maturation and activity of DCs, which normally promote T-cell alloreactivity inducing 
graft rejection. Furthermore, MSCs cultured with DCs in presence of differentiation 
stimuli, including LPS and TNF-α, obstruct the expression of CD83, MHC class II, 
CD40 or CD86 and induce also indirect expansion of Tregs[92,93]. 
Another important point to discuss is the activity of MSCs on NK cells, which are 
effector of innate immunity with cytotoxic activity toward cells that lack the 
expression of MHC class I[94].  
The NK cell activity depends on the balance between positive or negative signals 
induced by specific ligands express on target cells. Although resting MSCs express 
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low level of MHC class I, they are vulnerable to NK-mediated. This aspect can be 
explained by the presence of activating ligands on MSC surface, which move the NK 
cell balance toward to activate status. The NK activating ligands include the UL16-
binding proteins (ULBPs), the MHC class I-related molecule-1 (MICA/B), which are 
recognized by NKG2D receptors on NK cells, and nectin-2 (CD112) and Poliovirus 
receptor (PVR or CD155), which stimulate DNAX Accessory Molecule (DNAM-1). 
Interestingly, the IFN-γ stimulation of MSCs induces an overexpression of all NK 
activating ligands, but also the MHC class I molecule. The latter is the pivotal 
inhibitory ligand of NK cells and its overexpression induces MSCs to become 
resistance to NK-cytotoxicity[94,95]. 
MSCs inhibit also the proliferation of NK cells and this mechanism seems related to 
IDO, PGE2, TGF-β and HLA-G. Moreover, these molecules seem to reduce also the 
NK cell cytotoxicity versus target cells[74,95,96].  
In addition to the mechanism described on T and NK cell proliferation, primed MSCs 
are able to suppress the B cell proliferation, but how this regulation is carried out is 
still not clear[50,59]. MSC suppression on B cells involved also the reduction of 
antibody production and the release of chemokines responsible of B cell migration[97]. 
Finally, another important aspect to take into account in view of clinical application of 
MSCs is the capability of these cells to be immunoprivileged cells. In fact, MSCs 
cultured in presence of unstimulated T cells fails to induce lymphocyte activation[98]. 
This aspect can be explained by the lack of costimulatory molecules, including CD80 
or CD86 (B7 superfamily) on MSC membrane, which are essential for T-cell 
activation. T cells need to two different signals for activation that are, the MHC 
molecules associated with their antigen and the costimulatory molecules, recognized 
by the T-cell receptor and CD28 on T cell surface respectively. 
The low expression of MHC class I molecules and the lack of expression of MHC 
class II that CD80, CD86 or CD40 on MSCs prevent T cell activation.  
Interestingly, under inflammatory priming conditions MSCs overexpress both MHC 
molecules, but never express the costimulatory molecules, thus also in primed 
condition they are not able to activate T cell proliferation[50,99]. 
Overall, MSCs are immunoprivileged cells that modulate the balance of inflammatory 
response through activation or suppression of different IECs (Figure 5). MSCs support 
the development of inflammation by activation of monocyte differentiation toward the 
M1 phenotype and by release of chemokines involved in the recruitment of IECs. Once 
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inflammatory response has developed, the amount of cytokines levels stimulates the 
MSCs to become immunosuppressive. Licensing MSCs overexpress different genes, 
which produce immunosuppressive molecules, cytokines and growth factors, allowing 
the reduction of immune response and the induction of tissue repair.  
 
 
 
 
 
Figure 5. Role of inflammatory microenvironmental on MSC polarization. Representation of the capabilities of 
MSCs to differentiate toward proinflammatory or anti-inflammatory cells. As described in the text, low level of 
inflammatory cytokines, but also the activation of TLR-4, induce a switch toward the proinflammatory phenotype 
(MSC 1), which release chemokines involved in the recruitment of IECs and induce monocytes to differentiate into 
macrophages M1. Conversely, the higher concentration of cytokines, increased also by the continuous recruiting of 
IECs, together with the activation of TLR-3, induces MSCs to become immunosuppressive cells (MSC 2). Primed 
MSCs release different immunosuppressive molecules that regulate the IEC proliferation, induce monocyte via IL-6 
to differentiate into macrophages (M2) and produce various growth factor involved in the angiogenesis and tissue 
repair. 
 
 
 
1.2.3 Potential Application of MSCs 
 
The immunosuppressive and differentiation capabilities of MSCs, together with the 
ease isolation procedures of these SCs from different tissues, makes MSCs promising 
tools for the treatment of different degenerative and inflammatory diseases.  
The immunomodulatory effects of MSCs have been largely confirmed in different 
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disease models, including GvHD, experimental autoimmune encephalomyelitis (EAE), 
collagen-induced arthritis (CIA), inflammatory bowel disease (IBD), type 1 diabetes, 
and systemic lupus erythematosus (SLE)[100-105] and currently there are over 390 
active MSC-based trials worldwide.  
The first success of MSC therapy has been shown by using third-party haploidentical 
BM-MSCs to treat patients with cyclosporine and steroid resistant grade IV acute 
GvHD[106-108]. Similar effects have been demonstrated in other inflammatory 
diseases, including systemic lupus erythematosus and Crohn’s disease[107,108].  
However, many other studies have been shown their inefficacy. For example, in a 
mouse model of CIA, the intravenous administration of MSCs did not display any 
effect, while beneficial effects were showed after intraperitoneal injection of MSCs in 
a collagen-induced arthritis models[109,110].  
Similarly, conflicting data have been reported in mouse model of SLE. Allogenic MSC 
treatment in increased the progression of disease in lupus mice model (NZB/W mice), 
in contrast to the beneficial effect showed in MRL/lpr mice and in human clinical 
trials[100,111]. 
These failures seem related to the poor rate of MSC engraftment but also to the timing 
and the site of MSC administration. For instance, the effects of MSCs in acute GvHD 
model were ineffective when these cells were administrated at the same time of the 
GvHD onset. By contrast, multiple administrations of MSCs at weekly intervals 
efficiently prevented the development of the disease[112,113]. The beneficial effect 
seems related to the levels of cytokines, mainly IFN-γ, which induce a correct MSC 
licensing. In fact, the pretreatment of MSCs with inflammatory cytokines before their 
administration, led to a significantly improvement in GvHD mice model but also on 
concanavalin A-induced mice hepatitis[101,114]. 
Similar results in patients have been also reported. In fact, MSC administration did not 
shown any advantage when injected at the same time of HSC transplantation[115].  
Comparably, BM-MSCs were effective in EAE models only when they are 
administered at disease onset (days 3 and 8), but they are completely useless after 
disease stabilization (days 10 and 15)[116]. 
In future, it could be important to develop animal models that will make easier to 
understand the complex relationship between MSCs and host microenvironment, 
developing approaches for monitoring the inflammatory status of patients at the time of 
MSC infusion. Moreover, further studies will be important to understand the best 
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source and the passage in culture of MSCs, but also to clarify the differences between 
the application of autologous or allogeneic MSCs. Moreover, in depth analysis will be 
carry out to assess the MSC immunomodulation, increasing the experience in their 
clinical application, in order to provide reproducible data to their future clinical 
application. 
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1.3 Olfactory Ectomesenchymal Stem Cells (OE-MSCs) 
 
 
OE-MSCs are a subpopulation of SCs residing within the nasal olfactory 
mucosa[117,118]. The olfactory mucosa is a double-stratum organ separated by a 
basement membrane, including neuroephitelium that is located in front of the lumen, 
and the lamina propria, which is made up of Bowman glands that produce mucus, 
endothelian cells, ensheathing cells and SCs. Inside the olfactory mucosa there are two 
different types of SCs, that are neuroepithelian SCs and lamina propria SCs. The 
identity of neuroepithelian SCs has been debated for long time[119], moreover it has 
been demonstrated that these SCs have a relative poor proliferating rate, and a limited 
differential potential[120]. On the contrary, it has been shown that olfactory lamina 
propria SCs have a high proliferation rate and differentiate into neural and non-neural 
cell types both in vitro that in vivo. For instance, it has been demonstrated that OE-
MSCs can differentiate into dopaminergic cells when injected in rat models of 
Parkinson’s disease, and they are able to form cochlear hair cell-like cells[121,122]. 
These SC population do not shown any common markers neither with HSCs nor with 
NSCs, but they have similarity with MSCs in term of capability to generate 
mesodermal cell types, including osteoblasts and adipocytes, and expression of typical 
MSC markers, such as CD73, CD90 and CD105[117]. Moreover, since lamina propria 
is a connection tissue derived from mesenchyme, these SCs were defined as part of 
MSC family[117]. 
Conversely to nervous tissue samples, which are normally used to study molecular 
abnormality in brain diseases, the isolation of OE-MSCs does not have limitations. The 
olfactory mucosa is easily accessible in human and can be biopsied under local 
anaesthesia without any complications, for this reason OE-MSCs could be used for 
autologous transplantation.  
The role of OE-MSCs has been reported in different disease models. For instance, the 
beneficial effect of OE-MSCs has been shown in a mouse model in which 
ischemic/hypoxic injury was induced by exicitotoxically. In this brain-injured mouse 
model, transplanted OE-MSCs were able to migrate toward inflammation area, engraft 
into lesioned hippocampus, where they exhibited neural differentiation, stimulation of 
endogenous neurogenesis, and improved the physiological function of tissue[123]. In 
addition, the regenerative potential of OE-MSCs has been shown in a rodent spinal 
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cord injury model, where the transplantation of sphere-forming cells derived from OE-
MSCs supported axonal regeneration and induced astrocytic hypertrophy in the site of 
injury[124]. Moreover, it has been demonstrated the ability of OE-MSCs to 
differentiate into cardiomyocytes. When neurosphere-derived OE-MSCs were injected 
into infarcted rat heart restored the correct heart and ventricular function. 
All these data display the wide differentiation potential of this SC population, 
supporting them as promising candidates for stem cell-based therapies. 
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1.4 Leptomeningeal Stem Cells (LeSCs) 
 
 
LeSCs are a population of nestin positive SCs recently identified in rat leptomeninges 
by our group[125,126]. The isolation of this SC population has added new insights into 
the field of neural stem cells (NSCs), which are the major candidates for regenerative 
therapy in different neurodegenerative disease. Although, NSCs have shown self-
renewal properties and neuroglial differentiation, there are some limitations in their use 
in regenerative medicine, mainly related to the complex localization of these SCs and 
to the hardly accessible areas of central nervous system (CNV)[127].  
It has been demonstrated that neurogenesis from endogenous neural stem/precursor 
cells is localized in discrete areas of brain, that is the NSC niches, where NSCs are 
close contact with astrocytes, neuroblast, ependymal cells, endothelial cells. The 
synergic effect between the surrounding cells and microenvironment maintains NSC 
homeostasis, by regulating balance between proliferation and self-renewal[128]. NSC 
niche have been identified in different regions, including hippocampus, subventricular 
zone (SVZ), olfactory bulb, but also in non-neurogenic areas, such as spinal cord[129].  
Meninges are structured in three tissue membranes: the dura mater, which is the outer 
membrane that envelops the other meningeal layers, and the inner membranes, that are 
arachnoid and pia mater. The latter constitute the leptomeninges and are linked by 
arachnoid trabecular that span the subarachnoid space filled with cerebrospinal 
fluid[130]. Furthermore, leptomeninges are in close proximity of vessels, and penetrate 
deeply into the CNS parenchyma. In this way, the organization and localization of 
these membranes help the diffusion and distribution of activated precursor cells at 
specific sites.  
The primary function of meninges and cerebrospinal fluid is to protect the central 
nervous system (CNS). The leptomeninges constitute a complex microenvironment 
where different molecules (e.g. SDF-1/CXCR4), various cell types (e.g. pia mater 
cells, radial glia, neural precursor cells, Cajal Retzius cells, glia limitans cells) and 
extracellular matrix (e.g. laminin, collagen IV, fibronectin), support the development 
of cortex[131-137]. 
In 2009 our group isolated a nestin-positive cell population in brain meninges of 
embryonic and adult rodents, identified the leptomeningeal compartment as a new 
NSC niche. Leptomenigeal Stem Cells (LeSCs) were expanded in vitro both as 
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neurospheres, similarly to SVZ-derived NSCs, and as homogeneous cell population 
with SC features. LeSCs isolated by meningeal biopsies were able differentiate into 
excitable cells with neural morphology and phenotype, or into oligodendrocytes 
(Figure 6A), and showed the same capabilities also in vivo[125,126]. LeSCs showed 
self-renewal proliferative ability, and expressed doublecortin (DCX) in adult spinal 
cord meninges[125]. Moreover, nestin-positive cells were found also in human 
encephalic and spinal cord meninges[125,138]. Other research groups have been 
shown that human meninges cells expressed neural markers, including neurofilament 
protein and neuron-specific enolase when cultured in vitro[139-141]. 
 
 
 
 
 
Figure 6. Isolation and function of Leptomeningeal Stem Cells (LeSCs). In (A) it show how LeSCs derived from 
the inner membrane of leptomeninges (adult spinal cord) can be microdissected, expanded in vitro and induced to 
differentiate into neural cells. (B) A schematic representation of the activation of the SC niche in meninges 
following spinal cord injury is shown. LeSCs proliferate, increase in number and migrate inside the parenchyma 
contributing to the parenchymal reaction. (Modified from[130]). 
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The beneficial effects of LeSCs have been displayed in rat models of spinal cord injury 
(SCI)[125]. Contusive SCI induced the activation of meningeal niche, which was 
determined by the increase of thickness, SC proliferation and follow migration of 
LeSCs toward the site of injury (Figure 6B). The trauma induced the overexpression 
of genes in meningeal spinal cord cells, including stemness-related genes (such as 
Pou5f1/Oct4 and Nanog), and neural precursor markers, (such as Nestin, Dcx, Pax6 
and Klhl1)[142]. In vivo tracking analysis by use of specific marker have shown the 
presence of LeSC in different site of injury. Nestin-negative/DCX-positive cells were 
located into fibrotic scare, glial scar and also in perilesion parenchyma, demonstrating 
a differentiation toward neural cell type. 
In addition, other groups have been shown the regenerative capabilities of 
leptomeninges neural stem/progenitor cells in response to ischemia and post-stroke 
brain, showed their differentiation into neurons, astrocytes and 
oligodendrocytes[130,143]. 
Overall, these finding highlights the existence of new neural stem cell niche and 
highlight the effects of leptomeninges and their stem/precursor cells in the field of 
neurodegenerative diseases. However, further studies to understand the global 
mechanism of these SCs need to be clarified. 
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1.5 Amniotic Fluid Stem Cells (AFSCs) 
 
 
Amniotic fluid is a rich SC source easily achievable through amniocentesis, during 
standard diagnostic procedure of prenatal care.  
Several authors have shown the presence of different SC subpopulations inside the 
amniotic fluid. In 2003, Prusa et al. have been isolated for the first time a population of 
pluripotent SCs derived from amniotic fluids expressing Oct4 (octamer binding 
transcription factor 4), which is a pluripotent cell marker involved in maintaining of 
embryonic SCs differentiation and in self-renewal[144,145]. Subsequently, it has been 
demonstrated that AFSCs transfected with green fluorescent protein gene under both 
Oct4 and its transcriptional target Rex-1 promoter, were able to activate these 
promoters, confirming the presence of these transcription factors inside SCs derived 
from amniotic fluid[146,147]. 
Successively, other groups have reported the possibility of harvesting amniotic fluid 
cells displaying features of pluripotent stem cells[148,149], however, the existence of a 
subpopulation of c-Kit-posivitive SCs into amniotic fluid dates in 2005, when De 
Coppi et al have been isolated and characterized for the first time a cell population able 
to generate clonal cell lines, and to differentiate into lineages representative of three 
embryonic germ layers[150]. 
The isolation of c-Kit (CD117)-positive AFSCs includes two steps, that is the immune 
selection of CD117-positive cells derived from AF, following by expansion of these 
cells in culture (Figure 7)[151]. 
Once AFSCs adhere to plastic, they grow in a feeder layer and adopt a morphology 
ranging fibroblast-like to an oval-round shape. Moreover, they express MSC markers, 
such as CD73, CD90 and CD105, adhesion molecules, including CD29 and CD44, 
they are positive for MHC class I, but do not show positivity for hematopoietic and 
endothelian markers, including CD14, CD31 CD34, CD45, CD133, and for the MHC 
class II. Interestingly, AFSCs express also pluripotency-associated markers, such as 
Oct4 and NANOG and stage-specific embryonic antigen (SSEA-4)[150].  
It has been demonstrated that AFSCs are capable to differentiate in vitro towards cell 
lineages deriving from the three germ layers, including adipose, osteoblastic, 
myogenic, endothelial, neuronal, and hepatic cells, but these properties were not 
unequivocally confirmed in vivo.  
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Moreover, AFSCs can form embryoid bodies (EBs), a mechanism regulated by mTor 
pathway, which leads to a decreased expression of SC markers (e.g., nodal and Oct4) 
and an increased expression of differentiation markers (e.g., nestin-ectodermal, 
GATA4-endodermal and Brachyury-mesodermal)[152-154]. 
 
 
 
 
 
Figure 7. Isolation of c-Kit-positive Amniotic Fluid Stem Cells (AFSCs). Representation of isolation and 
expansion of CD117 positive cells from fresh amniotic fluid samples. After the first centrifugation, a fraction of the 
cell pellet can be used to analyze the level of markers present in the total population before culture and selection by 
flow cytometry. (modified[151]).  
 
 
 
Although AFSCs have a high proliferation rate and express pluripontency markers, 
they did not generate tumors when injected in immunodeficient mice[150,155].  
In addition, AFSCs can revert to a functional pluripotent state when cultured in small 
molecule cocktail, which are chemically induced pluripotent stem cells (iPS). More 
specifically, when AFSCs were cultured on Matrigel in human ESCs medium in 
presence of the histrone deacetylase inhibitor (HDACi) valproic acid (VPA), they 
acquired pluripotency, sharing similarities with human ESC transcriptome and with 
their capacity to form embryoid bodies (EBs) in vitro and teratomas in vivo[155,156]. 
These finding suggest that these iPS derived AFSCs could be utilized as pluripotent 
stem cells (iPS) for clinical use, but unlike iPS, they can be isolated early in pregnancy 
during termination procedures and are not at potential risk of virally induced 
tumorigenicity as they are reprogrammed with VPA. 
The therapeutic efficacy of AFSCs has been verified preclinical studies showing their 
capabilities to regenerate and improve the functionality of injured tissues and to restore 
cell niche homeostasis in muscle, bone, lung, and kidney[157-161]. The success of 
AFSCs in vivo is also correlated to their ability to cross the endothelial 
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barrier after systemic injection, thus engrafting into injured tissues[157,162,163].  
Recently, it has been displayed that AFSCs systemically injected into rats with cardiac 
damage did not rejected and were able to restore the functionality of damaged muscle, 
reducing the apoptosis, muscle atrophy and the level of proinflammatory 
cytokines[164]. Moreover, when injected into rat models of acute myocardial 
infarction, AFSCs released different molecules, such as carioprotective and pro-
angiogenic factors, which improved the damage and reduced the infarct area[165].  
Piccoli et al have shown that AFSCs re-established the muscle cell niche in an HSA-
Cre/Smnf7/f7 mouse model of spinal muscular atrophy, demonstrating the functional and 
stable long-term integration of these SCs into the skeletal muscle. AFSCs improved the 
survival rate of these animals, increased the muscle strength, showing their potentiality 
for the treatment of muscle diseases[158].  
The regenerative potential of AFSCs has been also investigated in bone formation and 
lung injuries. AFSCs cultured 3D scaffold and stimulated with BMP-7 were able to 
produce mineralized matrix[166]. In similar manner, AFSCs pre-treated with cytokines 
and cultured for three weeks in a 3D scaffold induced bone repair when injected in a 
critical sized femoral defect of rats[160].  
Also for the therapy of kidney disorders AFSCs have shown beneficial roles. In fact, 
AFSCs contributed in the nephrogenesis when injected in embryonic mouse models. 
Moreover, when injected in a model of acute kidney injury, AFSCs accumulated in 
peritubular capillaries and interstitium where reduced cell apoptosis and increased 
tubular proliferation[167-169]. 
When AFSCs integrate in damaged tissues they can carry out their beneficial effects 
through paracrine mechanisms. For example, AFSCs improved the kidney cell 
proliferation by release of different molecules, including glial cell line derived 
neurotrophic factor (GDNF)[161]. 
Finally, it has been demonstrated that AFSCs can integrate and differentiate into 
epithelial lung lineage, where they expressed alveolar and bronchiolar epithelial 
markers, including TFF1, SCP and CC10[157] in a hyperoxia lung damage. Here 
again, the release of different molecules by AFSCs allowing the recovery of lung 
structures in a rat model of bronchopulmonary dysplasia induced by hyperoxia[170]. 
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1.6 Cardiac Stem Cells (CSCs) 
 
 
For a long time the heart was considered as a postmitotic organ with a predetermined 
number of myocytes. According to this concept, the number of myocytes were 
established at birth and preserved until the death of individual, and the organ 
hypertrophy was restricted to myocyte enlargement[171-174]. 
Today, this old paradigm has been changed thanks to the discovery of SCs localized 
inside the heart. 
CSCs are a population of c-Kit positive SCs that have the capacity to differentiate in 
caridiomyocytes and coronary vessels. CSCs are localized in cardiac myocardium, 
inside interstitial microdomains where they support other neighbor cells, including 
cardiomyocytes and fibroblasts[175]. Inside the heart, CSCs maintain the SC pool 
through asymmetric divisions, and allow the differentiation of progeny[176]. 
In adult hearth, there is a balance between functionally-competent CSCs and senescent 
CSCs; however, in pathological condition this balance can shift toward the senescence, 
increasing the pool of apoptotic cells and resulting in a deregulation of cardiac niche 
and myopathy[177,178].  
In cardiac niche, CSCs are normally situated in atrial and apical myocardium, close to 
precursor cells, which are also positive for c-Kit receptor as CSCs, but express some 
myocyte markers, such as the contractile protein α-sarcomeric actin and the myocyte 
transcription factor Nkx2.5 (Figure 8)[179].  
Similarly to BM niche, inside myocardium the oxygen tension regulates the 
homeostasis of CSCs. For instance, a low concentration of O2 maintains CSCs in a 
quiescent and undifferentiated state; on the contrary normoxia could be necessary to 
regulate the CSC differentiation toward cardiomyocytes[13,180,181]. However, with 
aging the balance between hypoxia and normoxia is destabilized and produce an 
accumulation of hypoxic foci. This phenomenon leads to an increase of proliferating 
CSCs, toward a progressive reduction of CSC telomeres and formation of senescent 
dysfunctional cardiomyocytes[182].  
Several Authors have been shown the existence and the role that CSCs conducts inside 
myocardium. Resident SCs were labeled with nucleotide analogs or lentiviral 
fluorescent tags[175-177,181]. The periodic administration of BrdU or 3H-thymidine 
resulted in labeling of nuclei of cycling cells inside myocardium[183]. The cells with
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the higher fluorescence corresponded to the more undifferentiated cells having the 
lower proliferation rate, while a dilution of the label occurred in cells with a higher 
proliferation rate, corresponding to cells more differentiated. These experiments 
allowed the localization of CSCs inside myocardium, which corresponded to the 
brighter cells in the atria[183]. Moreover, this pool of slow-cycling SCs remained 
constant during the chasing period, demonstrating that CSCs tend to preserve the pool 
of undifferentiated SCs in the cardiac niche. 
 
 
 
 
 
Figure 8. Schematic representation of the cellular and extracellular components of a CSC niche. (modified 
from[179]). 
 
 
 
The differentiation potential of CSCs has been demonstrated both in vitro and in vivo. 
Transplanted CSCs are able to engraft within infarcted myocardium, differentiating in 
cardiomyocytes and coronary vessels[184-190]. 
Thus, CSCs are the more undifferentiated SCs inside the heart, and persist at all ages 
and with chronic heart failure. These finding have opened the way to a clinical 
application of these SCs in patients with severe ventricular dysfunction. It has been 
developed a method to isolate human functionally-competent CSCs from 
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endomyocardial biopsies from patients with advanced heart failure undergoing cardiac 
transplantation or implantation of ventricular assist device. When these SCs were 
cultured in vitro showed high myogenic and vasculogenic potential, and a high 
telomerase activity[191]. 
In a phase 1 trial SCIPIO (Stem Cell Infusion in Patients with Ischemic 
cardiomyopathy) c-Kit positive/lineage negative human CSCs are used for the 
treatment of chronic heart failure of ischemic origin[192,193]. After intracoronary 
injection, CSCs resulted efficacious in 7 out of 14 patients, while the others did not 
show adverse effects.  
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1.7 Lung Stem Cells (LSCs) 
 
 
LSCs are c-Kit positive SC type isolated and characterized for the first time in 2011. 
These cells are self-renewing, clonogenic, and multipotent in vitro. When human LSCs 
were injected into mouse lung in vivo, they were able to form human bronchioles, 
alveoli, functionally vessel inside the damaged lung of mouse[194]. 
Human LSCs are negative for pulmonary lineage markers and do not express epitopes 
of HSCs or MSCs, excluding their potential derivation from the BM. 
These SCs were found localized in bronchioles and in alveolar wall were they 
interacted with neighbor cells, such as epithelial cells, smooth-muscle cells and 
fibroblasts by adhesion molecules, which constituted the supporting cells in the LSC 
niches.  
For restoration of damaged lung to occur, the cells inside the organ have to be form 
both distal airways that distal pulmonary vasculature. The lung is constituted by 
different cells, which have regenerative potential but with the limitation to form a 
single cell type. For example, bronchoalveolar stem cells, Clara cells, side population 
cells, and type II alveolar epithelial cells are able to generate only type I and type II 
pneumocytes or stromal cells[195-198]. On the contrary LSCs can differentiate in 
different populations of epithelial cells and into pulmonary vessels, which have 
endodermal and mesodermal origin respectively[199].  
Moreover, the LSCs expressed the genes of pluripotency, that is homeobox 
transcription factor Nanog (NANOG), octamer-binding transcription factor 3/4 
(OCT3/4), sex-determining-region Y–box 2 (SOX2), and Kruppel-like factor 4 
(KLF4)[194]. 
These observations challenge the generally accepted belief that the lung is an organ 
lacking a hierarchical organization regulated by a compartment of resident SCs nested 
in the niche. 
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Aim of the work 
 
 
Adult SC-based protocols are a promising approach for the treatment of human 
degenerative diseases[101,106,115,116,200-202]; however, some immunological 
concerns for their clinical application derive from the possibility that either allogeneic 
adult SCs may be rejected by the host immune system due to 
histoincompatibility[203], or SCs themselves may interfere with the physiological 
functions of host immune system. As previously described, some kinds of SCs, such as 
MSCs, not only possess regenerative potential but also may interact with and 
profoundly influence the IECs[25,50]. On the other hand, immune system plays a 
pivotal role in the pathogenesis and progression of many degenerative diseases; 
consequently, the application of SC-based approaches could be effective in both 
regenerating damaged tissues and modulating the pathological immune reactions[100-
105,204,205]. For all these reasons, the immunogenicity and immunomodulatory 
properties of SCs must be carefully addressed before their clinical application.  
An important question that rises spontaneously is whether immune modulation is a 
common property that is shared by all SC compartments or it is a specific feature of 
some kinds of SCs that are physiologically in contact with the immune system. The 
answer to this question is still lacking, because a comparative, extensive and 
standardized characterization in vitro and in vivo of SC immunological properties has 
not been carried out so far. In fact, different stimuli, IECs, functional assays, culture 
conditions and animal models have been employed by many Authors to assess the 
immunological properties of SCs. 
Our study shows for the first time a comparison of different immunological features of 
various SC types derived from different tissues, in term of immunophenotype, 
immunomodulation, immunogenicity and anti-apoptotic capabilities. In particular, 
MSCs of different origin (bone marrow and olfactory mucosa), adult SCs from 
leptomeninges, amniotic fluid, and SCs isolated from myocardial and lung tissues, 
were examined by using of standardized assays, previously carried out in our lab[206].  
The aim of our study was to assess the role of the immunological licensing of SCs of 
different origin. In fact, for MSCs it is now clear that the redundant panel of 
immunoregulatory mechanisms is not constitutively expressed, but its induction 
requires a process of “licensing” that allows MSCs to exert their immune regulatory
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function. As previously described, this process implies: i) the “activation” of MSCs by 
means of inflammatory cytokines that are early produced by different cells as a 
consequence of antigen processing and IEC activation, such as IFN-γ or TNF-α; ii) the 
prevalence of priming stimuli on MSCs over signals that may hamper MSC inhibitory 
mechanisms, such as the triggering of TLRs by infectious agents or endogenous danger 
signals; iii) the timing of MSC engagement in the activation process of IECs. Many in 
vitro and in vivo data are available supporting the role of MSC licensing in the 
induction of a measurable and effective immune regulation[50-52]. The failure of some 
MSC-based protocols for immune modulation in animal models and in human clinical 
trials may be explained by either the lack of a proper licensing by inflammatory 
microenvironment or the wrong timing in MSC administration[50]. The optimization 
of SCs use for immune regulating purposes is required to maximize their beneficial 
effects. Thus, we compared the effect of licensing on the SCs of different origin above 
mentioned, to assess whether the immunological properties are equally inducible or 
there are some peculiarities. 
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Chapter 2 
 
 
 
 
Materials and Methods 
 
 
2.1 Isolation and culture of human SCs 
 
 
BM-MSCs (five samples) were isolated from BM aspirates of healthy donors 
(informed consent, approved by Ethical Committee of Azienda Ospedaliera 
Universitaria Integrata Verona; N. 1828, May 12, 2010 ‘‘Institution of cell and tissue 
collection for biomedical research in Onco-Hematology’’). BM aspirates were cultured 
in 225-cm2 flasks at 5x105 nucleated cells/cm2 concentration in alpha-minimal 
essential medium (α-MEM), 10% heat-inactivated fetal bovine serum (FBS), 100 
U/mL penicillin, and 100 mg/mL streptomycin (all from Gibco). After 72 h, non-
adherent cells were removed and the medium was replaced twice a week. Full 
characterization of BM-MSCs has been already described by our group 
elsewhere[59,60,206]. 
OE-MSCs (five samples) were obtained under a protocol approved by the local ethical 
committee (Comité de Protection des Personnes) of Marseille. Informed consent was 
given by each individual participating in the study, in accordance with the Helsinki 
convention (1964) and French law relating to biomedical research. OE-MSCs were 
purified as previously described[117]. Briefly, biopsies from the root of the medial 
aspect of middle turbinate or the septum in dorsomedial area were washed with 
Dulbecco modified Eagle medium (DMEM)/HAM F12 and digested for 1 h with 
dispase II solution (Boehringer). Then, the olfactory epithelium was removed from 
underlying lamina propria, which was cut into small pieces with 25 gauge needle. 
Tissue fragments were incubated with collagenase 1A to complete the tissue 
dissociation and, after centrifugation, the cell pellet was resuspended in α-MEM 
culture medium supplemented with 10% heat-inactivated adult bovine serum, 
100U/mL penicillin, and 100mg/mL streptomycin (all from Gibco). Full 
characterization of OE-MSCs has been already described by our group elsewhere[117]. 
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LeSCs (five samples) were obtained as previously described[126]from human 
brain/spinal cord samples including leptomeninges collected during neurosurgical 
procedures (informed consent, approved by Ethical Committee of Azienda Ospedaliera 
Universitaria Integrata Verona; N. 1974, June 1, 201i ‘‘Institution of meningeal cell 
and tissue collection for biomedical research in regenerative medicine for 
neurodegenerative and neurovascular diseases, and spinal cord injury’’). 
Leptomeninges were detached from neural parenchyma, dissociated, and washed with 
α-MEM; adherent cells were cultured in α-MEM, 10% heat-inactivated adult bovine 
serum, 100 U/mL penicillin, and 100 mg/mL streptomycin (all from Gibco). Full 
characterization of LeSCs has been already described by our group 
elsewhere[125,126]and are part of another specific article. 
AFSCs (six samples) were collected from confluent cultures of adherent cells derived 
from human amniocentesis carried out for diagnostic purposes (cytogenetic analysis), 
after mother’s informed consent; cells were harvested and immediately subjected to 
immunoselection. Sorted c-Kit positive AFSCs were grown in α-MEM medium 
(Gibco) containing heat-inactivated adult bovine serum, 100 U/mL penicillin, and 
100mg/mL streptomycin (all from Gibco), supplemented with 18% Chang B and 2% 
Chang C (Irvine Scientific). Full characterization of AFSCs has been already described 
by our group elsewhere[150,151]. 
CSCs and LSCs (three samples each) were obtained from enzymatic dissociation of 
myocardial and lung tissues, respectively, and cultured as adherent cells as previously 
described. Full characterization of CSCs and LSCs has been already described by our 
group elsewhere[184,194]. 
All SC types were detached (0.05% Tripsin-EDTA; Gibco) and harvested when 80% 
confluent, and then either reseeded at 103/cm2 concentration or frozen until use. All 
experiments were performed between passages 2 and 6. 
Each SC type was characterized in terms of phenotype and differentiation potential 
following ISCT-minimal criteria[32]. 
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2.2 Immunofluorescence 
 
 
SCs were harvested at 80% confluence and 2x104 cells were seeded on glass dishes 
pretreated with gelatin or poly-d-lysine (Sigma Aldrich) in 24-well plates. After 24h, 
cultures were fixed with 4% paraformaldehyde and stained with appropriate antibody: 
mouse-anti-human CD73-PE (BD Biosciences) for BM-MSCs, rabbit-anti-human 
nestin (Abcys) for OE-MSCs, mouse-anti-human nestin (BD Biosciences) for LeSCs, 
rabbit-anti-human c-Kit (DAKO) for AFSCs, CSCs, and LSC; as secondary antibodies, 
goat-anti-rabbit- AlexaFluor-549, goat-anti-mouse-AlexaFluor-488, and donkey-anti-
rabbit-FITC (all from Invitrogen) were used, respectively. Hoechst-33342 or TOPRO-
3 (Invitrogen) were added to reveal nuclei. Images were obtained by fluorescence or 
confocal microscopy at 20x or 40x magnification. 
 
 
 
 
2.3 Immunophenotyping 
 
 
SCs at 80% confluence were stimulated or not for 48 h with 10 ng/mL IFN-γ and 15 
ng/mL TNF-α (R&D Systems). The lack of cytotoxic effects of this inflammatory 
cytokines was previously confirmed[207]. Rested and primed SCs were stained with 
the following monoclonal antibodies against human markers: IgG1k-PE, CD54-PE, 
CD86-PE, CD106-PE, CD200-PE, and HLA-ABC-PE all from BD Biosciences; 
IgG1k-PE, CD80-PE, IgG1k-FITC, and HLA-DR-FITC all from Beckman Coulter; 
IgG1k-PE, CD112-PE, CD155-PE, IgG2b-PE, and CD274-PE all from Biolegend; 
IgG2a-PE, unconjugated IgG2a, MICA/B-PE, ULBP-1-PE, ULBP-2-PE, and 
unconjugated ULBP-3 all from R&D Systems, and goat-anti-mouse-PE from DAKO. 
For staining, 105 SCs were incubated with the selected monoclonal antibody or 
appropriate isotype control in PBS for 15 min at room temperature. For ULBP-3 
expression, PE-conjugated goat-anti-mouse IgG F(ab’)2 was added, after staining the 
cells with specific primary unconjugated antibody. According to manufacturer’s 
instruction, ULBP-1 expression was validated by intracellular staining using the 
Cytofix/Cytoperm kit (BD Biosciences). Data were analyzed by FACSCalibur and 
FACSCanto (BD Biosciences) and expressed as the ratio of geometric mean 
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fluorescence intensity (rMFI) obtained for each marker and its isotype-matched 
negative control. 
 
 
 
 
2.4 Immunomodulatory and survival assays 
 
 
IECs (CD3pos T cells, CD19pos B cells, and CD56pos NK cells) were purified from 
peripheral blood using appropriate negative selection kits (Miltenyi Biotec) with at 
least 95% cell purity, as evaluated by flow cytometry. In each well, rested and primed 
SCs were seeded with IECs at either 2x104 cell concentration (high ratio, 
corresponding to a confluent monolayer), or 2x103 cell concentration (low ratio). After 
SC adhesion, 2x105 T cells, 2x104 B cells, or 2x104 NK cells previously stained with 5 
mM carboxyfluorescein succinimidyl ester (CFSE) from Life Technologies, were 
added. T cells were activated with 0.5 mg/mL cross-linking anti-CD3 and anti-CD28 
antibodies (Sanquin) for 6 days in Roswell Park Memorial Istitute (RPMI) 
supplemented with 10% human AB serum. B cells were activated with 2 mg/mL 
F(ab’)2 anti-human IgM/IgA/IgG (Jackson Immunoresearch), 20IU/mL rhIL-2 
(Proleukin; Novartis), 50 ng/mL polyhistidine-tagged CD40 ligand, 5 mg/mL anti-
polyhistidine antibody (R&D Systems), and 2.5mg/mL CpG B (Invivogen) for 4 days 
in RPMI supplemented with 10% FBS (Invitrogen Life Technologies). NK cells were 
activated by 100 IU/mL rhIL-2 for 6 days in Iscove modified Dulbecco medium 
(IMDM) supplemented with 10% human AB serum. At the end of coculture, cells were 
detached by trypsin and stained with PerCP mouse anti-human CD45 monoclonal 
antibody from BD Biosciences and TOPRO-3 Iodide (Invitrogen Life Technologies); 
the proliferation was assessed on viable TOPRO-3neg CD45pos cells by FACS analysis 
as the percentage of cells undergoing at least one cell division. The proliferation rate 
was obtained according to the following formula: (percentage of CD45pos cell 
proliferation with SCs)/(percentage of CD45pos cell proliferation without SCs)x100. 
To evaluate the molecular pathways involved in immune regulation, the following 
specific inhibitors were added to SC/T cell cocultures: 1 mM L-N-monomethylarginin 
(L-NMMA), the inhibitor of inducible NO synthase (iNOS); 5 mM NS-398 (Cayman 
Chemicals), the inhibitor of cyclooxygenase-2 (COX-2) that is necessary for PGE2 
synthesis; 1mM L-1- methyltryptophan (L-1MT), the IDO inhibitor (Sigma-Aldrich); 2 
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mM tin-protoporphyrin (SnPP), the inhibitor of HO-1 (Frontier Scientific); and 10 
mg/mL purified anti-human IFN-γ NA/LE mouse IgG1 (BD Biosciences). 
To determine the IEC survival, primed and rested SCs were seeded with IECs at the 
same ratios used for the immunosuppression assays. Cells were analyzed after either 4 
days (B and NK cells) or 6 days of coculture (T cells). Cells were then harvested and 
stained with Allophycocyanin (APC) mouse anti-human CD45 BD Biosciences and 
lymphocyte survival was assessed following manufacturer’s instructions (PE active 
caspase-3 apoptosis kit; BD Biosciences). Briefly, fixed and permeabilized cells were 
stained with PE-anti-caspase-3 antibodies and cell survival was assessed as percentage 
of active-caspase-3neg CD45pos viable cells by FACS analysis. 
 
 
 
 
2.5 Immunogenicity assay 
 
 
Resting and primed SC immunogenicity was evaluated in a non-radioactive 
cytotoxicity assay using rh-IL-2 activated-NK cells as effector cells, following 
manufacturer’s instructions (Delfia Cytotoxicity kit; Perkin Elmer). Briefly, SCs were 
loaded with bis-acetoxymethyl terpyridine dicarboxylate (BATDA) fluorescent dye 
and then incubated for 3h with various ratios of allogeneic NK cells preactivated for 48 
h with 100 IU/mL rhIL-2. Cytotoxicity was quantified by assessing fluorescence 
release in coculture supernatants by a time-resolved fluorimeter (VictorTMX4, Perkin 
Elmer). 
 
 
 
 
2.6 Bioinformatics 
 
 
Hierarchical cluster analysis of protein expression was used to group SCs with similar 
expression pattern. Molecular markers with differential expression pattern among 
various SC types were selected from the rMFI derived from immunophenotyping. The 
expression data were logarithm transformed and grouped using hierarchical clustering 
algorithm in Gene Cluster 3.0 program[208]. Heat-map was performed using Java 
Treeview program[209]. 
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2.7 Statistical analysis 
 
 
Data were expressed as mean standard deviation, except for immunophenotype data 
that were expressed as mean ± standard error of the mean. Statistical analysis was 
performed by Prism software (GraphPad) using the Wilcoxon test to compare the 
effect of priming on the same SCs, while one-way ANOVA test was used to assess the 
differences among SCs types. P < 0.05 was considered statistically significant. 
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Results 
 
 
3.1 IFN-γ and TNF-α strongly regulate SC phenotype 
 
 
Previous reports have highlighted the differences among the SC types employed in this 
study in terms of marker expression, morphology (Figure 8.), differentiation potential, 
in vivo engraftment, and regenerative capabilities. The immunophenotype of resting 
and IFN-γ and TNF-α-primed BM-MSCs, OE-MSCs, LeSCs, AFSCs, CSCs, and 
LSCs was studied in parallel (Table 2, Table 3 and Figure 10), also by using a 
hierarchical cluster analysis (Figure 9). These SC types expressed HLA-ABC 
molecules at different levels. At baseline, HLA-ABC molecules were more abundant 
in OE-MSCs and LeSCs than in BM-MSCs, AFSCs, CSCs, and LSCs; however, 
following inflammatory priming, HLA-ABC molecules increased in all SC categories, 
and significant changes occurred in LeSCs (2.6-fold), AFSCs (2.2-fold), CSCs (2.0- 
fold), and LSCs (3.2-fold). In control conditions, HLA-DR was scarcely or partially 
expressed by BM-MSCs, but after inflammatory priming, it dramatically increased in 
BM-MSCs, OE- MSCs, and LSCs; low levels of HLA-DR were detected in primed 
AFSCs, LeSCs, and CSCs. The costimulatory molecules CD80 and CD86 were 
undetectable in all SC types with the exception of resting CSCs; however, CD86 was 
no longer detectable in CSCs after inflammatory priming. CD40 was weakly expressed 
in resting OE-MSCs and AFSCs, but a significant increase in CD40 was observed after 
inflammatory priming in BM-MSCs (3.2-fold), OE-MSCs (2.0-fold), and LeSCs (3.8-
fold). Primed AFSCs did not upregulate CD40, and CSCs and LSCs never expressed 
this marker. 
Two adhesion molecules CD54 (ICAM-1) and CD106 (VCAM-1), which are involved 
in cell migration and interaction between MSCs and inflammatory cells[85,210,211], 
were tested. CD54 was highly expressed in OE-MSCs, and low levels of this molecule 
were detected in the other SCs. CD54 was markedly upregulated in all primed SC 
types (BM-MSCs, 174.6-fold, OE-MSCs, 39.6-fold, LeSCs, 112.0-fold, AFSCs, 44.7-
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fold, CSCs, 47.0-fold, and LSCs, 129.0-fold). CSCs and LSCs did not express CD106 
at baseline, and only primed CSCs showed CD106 weakly.  
 
 
 
Figure 9. Representative immunofluorescence staining of various human stem cell (SC) types. (A) Bone 
marrow (BM)-mesenchymal stromal cells (MSCs) were stained with anti-CD73-PE (red) and TOPRO-3 (blue); (B) 
olfactory ectomesenchymal SCs (OE-MSCs) were stained with anti-Nestin (green) and Hoechst-33342 (blue); (C) 
leptomeningeal SCs (LeSCs) were stained with anti-Nestin (red) and TOPRO-3 (blue); (D) amniotic fluid SCs 
(AFSCs) were stained with anti-c-Kit (green) and TOPRO-3 (blue); (E) cardiac SC (CSCs) were stained with anti-c-
Kit (white) and TOPRO-3; (F) lung SCs (LSCs) were stained with anti-c- Kit (green) and TOPRO-3 (blue). Scale 
bars: 50 mm (A–C); 20 mm (D–F). 
 
 
 
Conversely, BM-MSCs, OE-MSCs, LeSCs, and AFSCs constitutively expressed 
CD106, which was significantly upregulated after priming (BM-MSCs, 4.3-fold, OE-
MSCs, 2.0-fold, LeSCs, 12.0-fold, and AFSCs, 14.0-fold). 
CD200 and CD274 (PD-L1) modulate the immune response via a cell-to-cell contact-
dependent mechanism[212-214]. CD200 was highly expressed in CSCs, modestly 
present in BM-MSCs and OE-MSCs, and absent in AFSCs, LeSCs, and LSCs. After 
inflammatory priming, a 2.7-fold downregulation of CD200 occurred in CSCs while 
no changes were observed in the other SCs. At baseline, CD274 was constitutively 
expressed in all SCs but mostly in OE-MSCs and AFSCs. Inflammatory priming 
resulted in a proportional upregulation of CD274 in the various SC categories. 
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Figure 10. Hierarchical cluster analysis of protein expression of various human SCs in resting and primed 
conditions. Modulation of expression of fifteen proteins in resting and inflammatory-primed conditions. Heat map 
showed the down (green) or upregulation (red) of protein expression. Different samples were grouped using 
hierarchical clustering algorithm. 
 
 
 
The NK cell-activating ligands were evaluated[96,215]. CD112 (nectin-2) and CD155 
Poliovirus receptor (PVR), which stimulate the DNAX Accessory Molecule-1 
(DNAM-1) receptor, were expressed at high levels in all SCs at baseline. Inflammatory 
priming increased by ∼ 2-fold the expression of CD112 and CD155 in all SCs but 
CSCs and LSCs.  
In the latter two cases, priming did not alter the levels of CD112 and CD155. The 
ligands of the NKG2D receptor, MICA/B and ULBPs, were then examined. ULBP-1, 
ULBP-2, ULBP-3, and MICA/B were not particularly abundant at resting conditions 
and after inflammatory priming in all SC populations. 
Overall, the immunophenotype observed at resting and inflammatory conditions show 
many similarities among different SC types; moreover, the clustering analysis 
highlighted a clear distinction between resting and primed SCs, which suggests a 
common pattern of protein modulation induced by inflammatory mileu (Figure 9). 
These data are in agreement with defective antigen-presenting cell functions 
Chapter!3:!Results!!
! 41!
(expression of HLA class I and class II molecules without coexpression of 
costimulatory molecules) and activating capability toward NK cells due to the partial 
expression of NK cell-activating receptors possibly leading to SC rejection; 
nevertheless, the latter activity may be counterbalanced following inflammatory 
priming by the upregulation of HLA class I molecules triggering inhibitory NK 
receptors. 
 
 
 
 
 
Figure 11. Expression of different markers on various human stem cells (SCs) in resting and primed 
conditions. Representative FACS analysis of different SC types showing the expression of HLA-ABC, HLA-DR, 
CD40, CD54 (ICAM-1), CD106 (VCAM-1), and CD274 (PD-L1) at resting and inflammatory conditions. Dashed 
curve indicates the isotype controls, while open and filled curves indicate resting and primed SCs, respectively. 
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SC Types  
 
Marker 
BM-MSCs OE-MSCs LeSCs AFSCs CSCs LSCs 
MHC and Costimulatory Molecules 
HLA-ABC 
16.97±2.48 29.42±5.46 22.83±4.32 11.29±2.98 5.15±0.17 2.74±0.1 
27.37±6.1 35.4± 5.47 59.34±10.2** 25.3±3.82** 10.37±0.66* 8.7±0.6* 
HLA-DR 
1.42±0.21 1±0 1.04±0.04 1.02±0.02 1±0 1.1±0.04 
21.91±3.61** 15.04±2.56* 1.58±0.17 2.66±0.91 3.53±0.1** 12.06±0.3** 
CD40 
1.29±0.14 1.93±0.17 1.19±0.12 2.1±0.26 1±0 1±0 
4.14±0.74* 3.8±0.27** 4.55±0.66* 2.4±0.07 1±0 1±0 
CD80 
1±0  1±0 1±0 1±0 1±0 1±0 
1.36±0.04 1±0 1±0 1±0 1±0 1.07±0.06 
CD86 
1.24±0.07 1.09±0.09 1.11±0.05 1.26±0.16 2.2±0.15 1±0 
1.02±0.02 1.34±0.31 1.18±0.18 1.17±0.09 1.06±0.05* 1±0 
Adhesion Molecules 
CD54 
6.83±2.68 35.28±6.51 9.67±1.2 14.04±4.78 4.43±0.9 2.1±0.14 
1193±98** 1400±156*** 1082±101** 626±60.9*** 208±14.54** 271±13.5** 
CD106 
5.8±2.08 6.11±1.54 2.06±0.19 1.89±0.27 1±0 1±0 
25.3±10.62 12.47±4.62 25±5.12* 26.58±7.3* 1.57±0.07* 5.16±0.4* 
Immunomodulatory 
CD200 
3.47±1.56 2.82±0.76 1.06±0.02 1.17±0.06 17.24±6.64 1±0 
3.73±1.06 1.86±0.45 1.15±0.12 1.18±0.1 6.03±0.42 1±0 
PD-L1 
5.28±0.55 15.68±2.68 2.17±0.14 23.88±4.2 3.72±0.21 4.37±0.1 
76.14±6.65** 96.42±26.51* 60.45±17.3* 80.2±12.7** 12.63±0.38*** 8.4±1.17** 
 
Table 2. Different expression of various markers involved in immunological effects of SCs. Cells were cultured 
for 48 h under normal or inflammatory conditions, stained with different antibodies and analyzed by flow 
cytometry. Data are presented as mean ± SEM of relative Mean Fluorescence Intensity (rMFI) of five (BM-MSCs, 
OE-MSCs, AFSCs, and LeSCs) or three (CSCs, LSCs) different experiments derived from resting (upper) and 
primed (below) SCs for each marker.*P < 0.05, **P < 0.01, ***P < 0.001. SC, stem cell; BM-MSC, bone marrow-
mesenchymal stromal cells; OE-MSC, olfactory ectomesenchymal SCs; LeSC, leptomeningeal SCs; AFS, amniotic 
fluid SCs; CSC, cardiac SCs; LSC, lung SCs.  
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SC Types  
 
Marker 
BM-MSCs OE-MSCs LeSCs AFSCs CSCs LSCs 
Activating NK ligands 
CD112 
11.87±2 30.86±4.75 12.5±4.33 23.7±1.37 7.18±1.21 4.95±0.26 
26.45±5.67* 62.38±8.78** 27.87±5.07** 33.8±4.2 5.23±0.02 3.54±0.16 
CD155 
17.9±3.78 57.86±12.8 57.82±20.35 78.48±17.9 7.9±1.47 6.23±0.44 
29.48±7.84 128.5±31 103.8±12* 102.7±13.04 6.88±0.04 8.2±0.3 
MICA/B 
1.7±0.24 1.19±0.17 1.07±0.08 1.75±0.4 1.57±0.06 1.15±0.02 
1.16±0.1 1.06±0.06 1±0 1.43±0.36 1.03±0.03 1.18±0.08 
ULBP-1 
1.79±0.21 1.43±0.08 1.43±0.04 1.23±0.02 1.14±0.06 1±0 
1.67±0.27 1.58±0.13 1.47±0.16 1.46±0.1 1.31±0.06 1±0 
ULBP-2 
3.73±1.8 2.47±0.28 2.31±0.45 3.12±0.55 3.84±0.02 1.4±0.01 
3.04±0.66 1.54±0.23* 2±0.3 1.88±0.23* 2.38±0.08 1.12±0.06 
ULBP-3 
2.3±1.04 1.3±0.27 1.16±0.12 1.64±0.59 2.2±0.07 3.24±0 
1.35±0.2 1.15±0.1 1.54±0.46 2.38±0.68 2.6±0.11* 1.04±0.03*** 
!
Table 3. Different expression of NK activating ligands on SCs. Cells were cultured for 48 h under normal or 
inflammatory conditions, stained with different antibodies and analyzed by flow cytometry. Data are presented as 
mean ± SEM of relative Mean Fluorescence Intensity (rMFI) of five (BM-MSCs, OE-MSCs, AFSCs, and LeSCs) or 
three (CSCs, LSCs) different experiments derived from resting (upper) and primed (below) SCs for each marker.*P 
< 0.05, **P < 0.01, ***P < 0.001. SC, stem cell; BM-MSC, bone marrow-mesenchymal stromal cells; OE-MSC, 
olfactory ectomesenchymal SCs; LeSC, leptomeningeal SCs; AFS, amniotic fluid SCs; CSC, cardiac SCs; LSC, 
lung SCs. 
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3.2 SCs share immunomodulatory properties 
 
 
MSCs from several organs exert comparable regulatory effects on cells belonging to 
the innate and acquired immunity. Thus, we determined whether the variety of SC 
types included in the current study possessed similar immunological properties. 
Resting or primed SCs were cocultured with purified T-, NK-, and B cells to evaluate 
their ability to induce proliferation of unstimulated IECs. All SC types neither 
activated nor promoted IEC growth (data not shown). Then, the role of SCs in IEC 
replication was assessed by using different IEC:SC ratios, which ranged from 10:1 
(high ratio) to 100:1 (low ratio) for T cells, and from 1:1 (high ratio) to 10:1 (low ratio) 
for NK and B cells, according to the standardized approach previously used with BM-
MSCs[206]. At resting and primed conditions, none of the SC types displayed a 
modulatory function on IECs at low ratios (data not shown). Conversely, at high 
ratios, all SCs inhibited T cell division at resting conditions, and significantly more 
following pretreatment with inflammatory cytokines (Figure 11). OE-MSCs, LeSCs, 
CSCs, and LSCs showed a greater immunomodulatory effect than AFSCs and BM-
MSCs. 
All SCs with the exception of LeSCs displayed inhibitory properties on NK cells in 
absence of pretreatment with IFN-γ and TNF-α (Figure 12). Resting and primed OE-
MSCs inhibited proliferation of NK cells by more than 90%. Resting LSCs and CSCs 
had an intermediate effect on NK cell proliferation, and BM-MSCs and AFSCs had the 
lowest. Primed BM-MSCs had a partial enhanced immunosuppressive activity, a 
response that was not detected in AFSCs, LSCs, and CSCs. LeSCs had no effect at 
baseline but, following priming, manifested a strong immunodulatory function 
comparable to OE-MSCs, and higher than BM-MSCs. 
In the absence of inflammatory stimuli, MSCs cannot inhibit B cell growth due to the 
lack of IFN-γ release[59]. Although resting LSCs enhanced B cell proliferation, the 
other resting SC types failed to demonstrate any immunomodulatory function on B 
cells (Figure 13). However, primed SCs inhibited B cell replication. OE-MSCs and 
LeSCs showed an effect that was significantly greater than in the other SCs including 
BM-MSCs. Collectively, distinct SC categories possess common immunomodulatory 
properties, which at times differ qualitative and quantitatively (Table 4). 
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Figure 12. HumanSC inhibitory effect on stimulated T cell proliferation. Human T cells (were stimulated with 
anti-CD3 and anti-CD28 and cultured alone (  bar) or in the presence of resting (  bars) or primed (  bars) 
allogeneic human SCs. At the end of coculture, lymphocyte proliferation was assessed using carboxyfluorescein 
succinimidyl ester (CFSE) dilution method, as described in Materials and Methods section. CFSE fluorescence was 
analyzed after 6 days at 10:1 T/SC ratio. The results are expressed as relative proliferation percentage of IEC, 
normalized to IEC cultured alone (100%). Error bars represented mean ± SD of five independent experiments for 
BM-MSCs, OE-MSCs, LeSCs, and AFSCs and three independent experiments for CSCs and LSCs. **P < 0.01, 
***P < 0.001. 
 
 
 
 
 
Figure 13. Human SC inhibitory effect on stimulated NK cell proliferation. Human NK cells were stimulated 
with IL-2 and cultured alone (  bar) or in the presence of resting (  bars) or primed (  bars) allogeneic human 
SCs. CFSE fluorescence was analyzed after 6 days at 1:1 NK/SC ratio. The results are expressed as relative 
proliferation percentage of IEC, normalized to IEC cultured alone (100%). Error bars represented mean ± SD of five 
independent experiments for BM-MSCs, OE-MSCs, LeSCs, and AFSCs and three inde- pendent experiments for 
CSCs and LSCs. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Figure 14. HumanSC inhibitory effect on stimulated B cell proliferation. Human B cells were stimulated with 
specific F(ab’)2 anti-human IgM/IgA/IgG, rhIL-2, CD40 ligand, anti-polyhistidine antibody, and CpG, and then 
were cultured alone (  bar) or in the presence of resting ( bars) or primed ( bars) allogeneic human SCs. 
CFSE fluorescence was analyzed after 4 days at 1:1 B/SC. The results are expressed as relative proliferation 
percentage of IEC, normalized to IEC cultured alone (100%). Error bars represented mean ± SD of five independent 
experiments for BM-MSCs, OE-MSCs, LeSCs, and AFSCs and three inde- pendent experiments for CSCs and 
LSCs. **P < 0.01, ***P < 0.001. 
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3.3 Molecular pathway in SC-mediated immunomodulation 
 
 
To dissect the mechanisms responsible for the impact of SCs on T cell division, 
specific inhibitors (L-1MT, LNMMA, NS-398, and snPP) were added to SC-T cell 
cultures at doses that did not alter T cell viability and growth. The neutralizing anti-
IFN-γ monoclonal antibody was also used to define the role of this cytokine in immune 
modulation. With the exception of resting OE-MSCs, L-1MT completely rescued T 
cell proliferation in the presence of resting or primed SCs; this result indicates that 
IDO is a major determinant of the anti-proliferative effects that SCs have on T cells 
(Figure 14). Conversely, inhibitors COX-2 (NS-398), HO-1 (snPP), and IFN-γ 
blocking antibody only partly restored T cell replication. The iNOS inhibitor 
LNMMA, however, failed to restore T cell division in the presence of either resting or 
primed human SCs (data not shown). NS-398 interfered with PGE2 synthesis 
attenuating the effects of resting LeSCs and primed BM-MSCs. Interestingly, snPP-
mediated HO-1 inhibition modestly reactivated CSC-induced T cell suppression.  
Collectively, our observations suggest that the anti-proliferative effects of SC types on 
T cells is predominantly driven by the activation of IDO and the degradation of 
tryptophan (Figure 14), an essential factor for T cell division and the generation of 
kynurenine, a critical immunomodulatory molecule. 
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Figure 15. Effect of specific inhibitors on T cell proliferation. Stimulated T cells were cultured alone (  
bars)or in presence of different resting (  bars) and primed ( bars) SC types (at 10:1 T/SCs ratio). In each 
coculture the following inhibitors were added both on resting (  bars) and primed ( ) SC/T cell coculture: L-
1MT (A), Anti-IFN-g (B), NS-398 (C), and snPP (D). After 6 days, cells were harvested and T cell proliferation was 
evaluated by FACS analysis. The results are expressed as relative proliferation percentage of T cells, normalized to 
T cells cultured alone (100%). Error bars represented mean ± SD of five independent experiments for BM-MSCs, 
OE-MSCs, LeSCs, and AFSCs and three independent experiments for CSCs and LSCs. *P < 0.05, **P < 0.01, ***P 
< 0.001. 
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3.4 SC immunogenicity and NK-mediated lysis 
 
 
Treatment of BM-MSCs with inflammatory cytokines reduces the susceptibility of 
these cells to NK cell-mediated lysis[96]. This phenomenon is initiated by the 
expression in BM-MSCs of surface molecules, induced by the inflammatory milieu, 
which have the ability to activate or inhibit NK receptors[215,216]. These ligands, 
including CD112, CD155, MICA/B, ULBPs, and HLA class I and II molecules, are 
present in the SC types studied here (Table 2 and Table 3). To assess whether SCs are 
sensitive to NK cell-mediated cytotoxicity, BATDA stained-SCs were cocultured with 
different ratios of IL-2-stimulated NK cells. Cytotoxicity activity was measured by the 
quantity of BATDA released in the medium that is proportional to NK cell-mediated 
lysis. NK cells were capable of partially lysing resting SCs, and this effect was directly 
proportional to the increase of NK/SC ratio (Figure 15). However, an opposite effect 
was observed when SCs were pretreated with IFN-γ and TNF-α; SCs were 
significantly less vulnerable, suggesting that the differential expression of surface 
molecules attenuates the susceptibility of SCs to NK-mediated lysis. 
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Figure 16. Immunogenicity of resting and primed human SCs. To evaluate NK cytotoxicity, SCs were labeled 
with BATDA (as reported in Materials and Methods section) and cocultured with IL-2-stimulated NK cells at 
different NK/SC ratios. The amount of cytotoxicity was calculated as release of fluorescence by lysed SCs, and 
detected by time-resolved fluorimeter (Victor X4 Multilabel Plate Reader, PerkinElmer). Each graphic shows the 
results obtained from five independent experiments, in which resting (blu line) and primed (red line) SCs were used 
as target cells. Data are expressed as percentage of fluorescence release. Error bars represented mean ± SD of five 
independent experiments for BM- MSCs, OE-MSCs, LeSCs, and AFSCs and three independent experiments for 
CSCs and LSCs. *P < 0.05, **P < 0.01, ***P < 0.001. BATDA, bis-acetoxymethyl terpyridine dicarboxylate. 
 
 
  
1:1 5:1 15:1 25:1
0
50
100
***
*** ***
1:1 5:1 15:1 25:1
0
50
100
***
***
***
1:1 5:1 15:1 25:1
0
50
100
*
** **
1:1 5:1 15:1 25:1
0
50
100
***
***
*** ***
1:1 5:1 15:1 25:1
0
50
100
*
***
***
1:1 5:1 15:1 25:1
0
50
100
*
***
***
***
BM-MSCs OE-MSCs
LeSCs AFSCs
CSCs LSCs
%
 Sp
ec
ifi
c R
ele
as
e
Chapter!3:!Results!!
! 51!
3.5 SC and lymphocyte survival 
 
 
Resting MSCs prevent T cell apoptosis promoted by the engagement of T cell 
receptors[217]. On the basis of these observations, we tested whether different SC 
types were capable of protecting IEC survival and whether this effect was modulated 
by inflammatory priming. Unstimulated T, NK, and B cells were cultured alone or in 
presence of either resting or primed SCs at different ratios. After 4 days (B and NK 
cells) and 6 days (T cells), cocultured cells were harvested and stained with anti-active-
caspase 3 antibody, and analyzed by flow cytometry. Resting and primed SCs 
significantly reduced IEC apoptosis (Figure 16). This phenomenon was less apparent 
in T cells, possibly due to the higher survival of this cell type with respect to B and NK 
cells. We also found a dose-dependent anti-apoptotic effect of BM-MSCs, OE-MSCs, 
and LeSCs on B cells. 
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Figure 17. Trophic support of resting and primed human SCs on different immune effectors. Resting and 
primed SCs were cocultured with unstimulated human IECs (ie, T, B, and NK cells). At the end of coculture, 
immune cell survival was detected by measuring cytosolic active-caspase-3 (as reported in Materials and Methods 
section). The results are expressed as percentage of caspase-3negCD45pos cells, and the analysis was performed by 
flow cytometry. Error bars represented mean ± SD of five independent experiments for BM-MSCs, OE-MSCs, 
LeSCs, and AFSCs and three independent experiments for CSCs and LSCs. *P < 0.05, **P < 0.01, ***P < 0.001. 
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SC Types/IECs 
Immune Modulatory Effect Molecular Mechanism Immunogenicity 
T  NK  B  T  NK  
BM-MSCs + + ≅ IDO *** 
pBM-MSCs ++ + ++ IDO * 
OE-MSCs ++ +++ - // *** 
pOE-MSCs ++ +++ +++ IDO * 
LeSCs +++ ≅ - IDO/COX-2 *** 
pLeSCs +++ +++ +++ IDO * 
AFSCs + ≅ ≅ IDO/IFN-γ *** 
pAFSCs ++   + IDO/IFN-γ * 
CSCs +++ + - IDO/HO-1 *** 
pCSCs +++ + ++ IDO ** 
LSCs +++ + - IDO *** 
pLSCs +++ + +++ IDO ** 
 
 
Inhibition Range (%) Symbol 
Supportive effect - 
0-20 ≅ 
20-50 + 
50-75 ++ 
>75 +++ 
  
Susceptibility to NK-mediated lysis (%) Symbol 
0-30 * 
30-50 ** 
>50 ** 
 
Table 4. Results derived from immunomodulatory and immunogenicity assays are summarized to compare different 
SC type behavior; p:inflammatory primed. For immunogenicity assay, NK:SC ratio is 25:1 
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Conclusions 
 
 
Cell loss, inflammation, immune system activation, and cell renewal occur following 
tissue injury. Alterations in this sequence of events result in inadequate organ repair 
giving rise to pathologic states[25,205,218,219]. Inflammatory priming has been 
viewed as a requirement for MSCs to have immune modulatory properties in vitro and 
in vivo[25,50,101,106,115,204,220]. The origin of MSCs, the secretion of soluble 
factors conferring proper SC licensing, and the level of inflammation at the site of cell 
delivery may account for some of the differences reported in the literature[50]. 
However, the immune modulatory function of BM-MSCs has been documented in 
graft-versus-host disease[101,106,115], autoimmune encephalomyelitis[102],  
sepsis[201], collagen-induced arthritis, and bowel inflammation[103-105]. But whether 
other SC categories have the ability to exert comparable effects was unknown and our 
results provide novel information supporting the view that a variety of SCs share the 
critical aspect of being immune privileged.  
An important distinction has to be emphasized among the SC types analyzed here. It is 
generally considered that the regenerative potential of transplanted SCs may be exerted 
either directly, through the engraftment of SCs inside the damaged tissue followed by 
proliferation and differentiation into novel terminally differentiated cell progeny, or 
indirectly, through the release of soluble factors favoring the healing processes 
mediated by resident SCs and contrasting the negative effect of inflammatory 
phenomena. The predominant therapeutic efficacy of MSCs and MSC-like SCs is 
mediated via a paracrine mechanism associated with the release of several cytokines 
that profoundly influence the response of IECs[59,65,83,95,221-224]. This principle 
applies to all SCs that modulate inflammation and have a limited capacity to generate a 
specialized progeny. However, they indirectly activate resident SCs, enhancing the 
repair of the organ[225-227]. Because of these characteristics, therapeutically, MSCs 
and MSC-like SCs may have to be repeatedly employed to exert their role long-term, 
in absence of clear evidence of their homing and persistence inside the 
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tissues[100,102-105,204,205]. Conversely, the delivery of tissue-specific multipotent 
adult SCs, such as CSCs and LSCs, to the corresponding damaged organ fails to 
stimulate the resident SCs nested in proximity to or distant from the injured 
parenchyma[196,228]. Their exclusive beneficial effect is linked to their engraftment, 
expansion, and ultimately the regeneration of functionally-competent cells and 
vessels[184,194]. Thus, two important aspects have to be discussed. First, the 
recognition obtained in the current study in vitro that the analyzed SCs interfere with 
the inflammatory microenvironment is strongly consistent with their inherent ability to 
home to and divide within the damaged tissue, which has been previously 
demonstrated experimentally[123-126,157,158,194,196,228], in absence of 
inflammation in the parenchyma surrounding the integrated SCs shortly after their 
administration, or chronically in the regions adjacent to the regenerated tissues. In 
other words, our data suggest that the immune modulatory properties of SCs here 
described in vitro for the first time may have a role in vivo in favoring their 
regenerative potential. Secondly, all SCs become structurally and functionally coupled 
with the cells of the recipient organ, creating new niches in which the SCs can divide 
asymmetrically[123-126,157,158,194,196,228], thus ensuring the preservation of the 
SC pool and the formation of parenchymal and vascular cells[176,184,194]. It is likely 
that the potential clinical implementation of these SC populations is significantly 
strengthened by their immunomodulatory function. In vivo studies with each SC type 
are mandatory to assess the role of these immunological features in SC engraftment 
and regenerative potential. Further in vivo studies in animal models will clarify the 
immunological results obtained here. 
As far as the general features related to the acquisition of the immune regulatory 
functions are concerned, the immunophenotype of the different SCs revealed a 
common switch, in response to inflammatory priming, from a resting to an activated 
immunosuppressive pattern. This change included the upregulation of HLA class I, the 
adhesion molecules ICAM-1 and VCAM-1, and the immunosuppressive molecule PD-
L1 (CD274). Importantly, ICAM-1, VCAM-1, and PD-L1 strongly bind to IECs 
promoting cell-to-cell contact and exposing immune cells to immunosuppressive 
molecules[85,212,213]. A de novo expression of MHC class II was detected and, 
although this adaptation may theoretically favor an immune cell response, lymphocyte 
activation was never detected when cocultured with the variety of SC types 
investigated here. This result may reflect the absent or weak expression of the co-
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stimulatory molecules CD80 and CD86. 
Our observations indicate that resting and primed SCs enhance the viability of 
unstimulated IECs rather than inhibiting their function. All SC types show an anti-
apoptotic effect on T, B, and NK cells, suggesting that their potential inhibitory 
role[50] is not a constitutive property of SCs, but is acquired through IEC activation. If 
SCs are not inflammatory-primed and are challenged with activated NK cells, the 
resulting interaction is SC lysis. However, IFN-γ and TNF-α licensing makes SCs 
resistant to NK cells, a characteristic particularly apparent for B cell proliferation. A 
similar requirement has previously been shown for MSCs[96]. 
Here, we found that the exposure to inflammatory milieu leads to IDO activation that 
becomes the central immunosuppressive enzyme affecting T cell proliferation in all SC 
types, as shown previously also by other authors[65,223], even if some other 
molecules may be involved. The discrepancies among different published data could 
be related to different experimental approaches; thus, method and assay 
standardization is required to obtain comparable results, as suggested by ISCT MSC 
Committee[229]. 
In summary, our findings have provided new information concerning the immune 
modulatory properties of several SC types, an attribute that was previously unknown. It 
is now clear that immunomodulation is not a peculiar feature of MSC-like cells, but 
actually a general property of SCs that may be induced or enhanced by inflammatory 
stimuli. SC niches may be viewed as immunological structures playing a fundamental 
role in tissue homeostasis, by regulating the interplay of SCs and IECs, which 
promotes cell survival. With persistent antigen activation and immune responses, the 
immunological SC niche may become an important variable of the pathogenesis and 
progression of degenerative diseases. Understanding these mechanisms may help 
identifying novel therapeutic strategies or recognizing the most effective SC class able 
to interfere with damage-mediated inflammation, and to induce tissue regeneration and 
organ repair. 
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